How long should I wait to see the results of leriglitazone?

Leriglitazone is still in the early stages of clinical development, but existing clinical trial data didn’t find a benefit of the therapy in Friedreich’s ataxia (FA) patients over a year of treatment with respect to spinal cord atrophy (wasting), a measure that’s thought to correlate with clinical disease progression. Data on secondary measures, however, suggested a potential benefit of leriglitazone regarding metabolic biomarkers and in preventing a decline in upper limb ataxia after 48 weeks of treatment. Additional clinical trial data will be needed to further establish the potential benefits of leriglitazone in FA.